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The recombinant murine immune interferon (rMu-IFN-y) was purified to homogeneity from Escherichia 
coli harboring the expression vector of murine IFN-y. The purified rMu-IFN-y showed an IU, of 15000 
in SDS-polyacrylamide gel electrophoresis. Results of amino acid analysis, amino- and carboxyl-terminal 
analyses and peptide mapping of rMu-IFN-y suggest hat it has the complete protein sequence predicted 
on the basis of cDNA except for lack of four amino acid residues from the mature carboxyl-terminus. 
Recombinant murine immune interferon Purijication Terminal analysis Pep t ide mapping 
1. INTRODUCTION 2. EXPERIMENTAL 
As the immune interferon (IFN-y) has a strict 
species specificity, murine IFN-7 (Mu-IFN-y) 
should be used in murine model systems which 
have been used for the study on the action of IFN- 
7. Mu-IFN-y has been isolated from spleen 
cultures [l] and T-cell lines [2]. The cDNA of Mu- 
IFN-y was cloned and expressed by Gray and 
Goeddel [3] in order to clarify the possibility of 
contamination of natural IFN-7 with other lym- 
phokines and also to provide sufficient material. 
However, detailed molecular characterization of 
both natural and recombinant Mu-IFN-ys has not 
yet been performed. Here, we describe the 
purification and characterization of recombinant 
murine IFN-7 (rMu-IFN-y) produced in 
Escherichia coli. 
Abbreviations: rMu-IFN-y, recombinant murine im- 
mune interferon; HPLC, high-performance liquid 
chromatography; SDS-PAGE, polyacrylamide gel elec- 
trophoresis 
2.1. Isolation of Mu-IFN-y cDNA and 
construction of expression plasmid 
Mu-1FN-y cDNA was isolated from the cDNA 
library constructed from concanavalin A-induced 
B5 cells [4] by the method of Okayama and Berg 
[5], which will be described in detail elsewhere. The 
nucleotide sequence encoding mature Mu-IFN-y 
was placed under the control of the trp promoter 
essentially as described by Gray and Goeddel [3]. 
2.2. Expression of rMu-IFN-y in E. coli and 
purification 
LB and M9 media were prepared as in [8]. E. 
coli K-12 strain C600 was used for the expression 
of rMu-IFN-y. The cultures (100 ml) were grown 
overnight in LB medium supplemented with am- 
picillin (40 mg/l), and then diluted into 10 1 of M9 
medium containing 0.5% glucose, 0.5% casamino 
acid, 40 mg/l ampicillin. After growth at 37°C 
under vigorous agitation and aeration, E. cofi cells 
were harvested by centrifugation. The rMu-IFN-y 
was purified by a combination of anion-exchange, 
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hydrophobic and size-exclusion chromatographies 
after cell disruption and ammonium sulfate frac- 
tionation. 
2.3. Amino acid analysis and determination of 
terminal sequences 
Samples were hydrolyzed according to Simpson 
et al. [7] and amino acids were analyzed with a 
Hitachi model 835 amino acid analyzer. Edman 
degradation was performed as described by 
Iwanaga et al. [8] with slight modifications. The 
carboxyl-terminal sequence was characterized by 
digestion with carboxypeptidase P (Protein 
Research Foundation). 
2.4. Peptide mapping of Mu-IFN-y 
Reduced and S-carboxymethylated rMu-IFN-y 
(RCm-Mu-IFN-y) prepared according to 
Crestfield et al. [9] was dissolved in 6 M guanidine 
hydrochloride and chemically modified with suc- 
cinic anhydride. The modified protein was in- 
cubated for 4 h at 37°C with Staphylococcus 
aureus protease [Miles Laboratories, 2% (w/w) of 
rMu-IFNy], and then directly subjected to 
reversed-phase HPLC for peptide mapping. 
3. RESULTS 
3.1. Purification of rkiu-IFN-y from E. coli 
About 80 mg pure rMu-1FN-y protein was ob- 
tained from 100 g wet cells with an overall 
recovery of 12%. The specific activities of some 
final preparation batches were 2-6 x 10” units/mg 
protein (vesicular stomatitis virus and mouse LO 
cells with mouse cu/fl international reference stan- 
dard) and in close agreement with that reported by 
Burton et al. [lo]. 
3.2. Purity of the final Mu-IFN--y preparation 
One major protein band at 15 kDa and another 
faint band at 30 kDa were observed by SDS-PAGE 
(fig.1). The minor band at 30 kDa increased when 
samples were treated without 2-mercaptoethanol 
(2-ME) prior to electrophoresis and seemed to be 
an undissociated imeric form as observed in the 
case of natural human [l l] and murine [12] IFN- 
ys. This undissociated imeric form was less than 
3% in the presence of 2-ME, and any other impuri- 
ty bands were not observed in the dye-stained gel. 








d e f 
Fig. 1. SDS-PAGE pattern of rMu-IFNy. Purified rMu- 
1FN-y (b and c, 10 /cg; d and e, 20 cg) was treated with 
(b,d) or without 2-ME (c,e) and subjected to SDS- 
PAGE. The gel was stained with Coomassie brilliant 
blue R-250. Molecular masses (in kDa) of marker 
proteins (a$) are indicated by arrows. 
analytical HPLC pattern (not shown) suggesting 
the purity of almost 100%. 
3.3. Protein chemical characterization of purified 
rMu-IFN-y 
Table 1 shows the amino acid composition of the 
final preparation. Most values were in good agree- 
ment with the theoretical ones predicted from 
cDNA, while Ser, cysteic acid and Arg were one or 
two residues less than the theoretical values. Ed- 
man degradation of RCm-Mu-INF-y suggested the 
single amino-terminal sequence of NHz-carboxy- 
methylcysteine (CmCys)-Tyr-CmCys-His-Gly- con- 
sistent with that predicted from cDNA. Fig.2 
shows the liberation of amino acids from RCm- 
Mu-IFN-y by carboxypeptidase P, suggesting a 
sequence of -Ser-Leu-(Arg 2, Lys 2)COOH as the 
carboxyl-terminus. Considering the theoretical 
protein sequence and the results of amino acid and 
carboxyl-terminal analyses, the actual carboxyl- 
terminus of purified rMu-IFN-y should be Lys 132 
and four residues from the mature carboxyl- 
terminus (Arg 133-Ser-Arg-Cys 136) should be 
completely truncated. Fig.3 shows the peptide 
mapping pattern of RCm-Mu-IFN-y by HPLC. 
All peaks were collected, rechromatographed and 
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Table 1 
Amino acid composition of rMu-1FN-y 
Observed Theory 
Asp 17.0 17 
Thr 2.9” 3 
Ser 14.3” 16 
Glu 17.1 17 
Pro 2.2 2 
Gly 3.3 3 
Ala 5.4 5 
cys/2 1.7b 3 
Val 8.0’ 8 
Met 2.0 2 
Ile ll.jc 12 
Leu 13.0 13 
T yr 2.7 3 
Phe 8.9 9 
Lys 10.0 10 
His 2.8 3 
Trp 1.9 2 
Arg 6.0 8 
Total 136 
* Values corrected to 0 h hydrolysis 
b Value of cysteic acid after performic acid oxidation 
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Fig.2. Liberation of amino acids from RCm-Mu-IFN-y 
by carboxypeptidase P. RCm-Mu-IFNT was incubated 
with carboxypeptidase P [O.lQo (w/w) rMu-IFN-y] in 
50 mM sodium acetate buffer @H 3.7) containing 0.1 Qo 
Triton X-100. At appropriate times aliquots were 
withdrawn and subjected to amino acid analysis. 
SP-8 SP-7 SP- 5 sq- 3 
I I I 
30 40 50 60 min 
Fig.3. Reversed-phase HPLC pattern of succinyl RCm-Mu-IFNT after digestion with S. aureus protease. 
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::-,-,-,-,-,-,-,_E_~O-L_*_s-L_N_*_Y_*_N_~~s_G_I_D_Y_E_E_K_S_~~F_~_D_I_W_R_N_W_Q_~OD_G_D_~_~_~_~_~_s_~~ 
t+--- SP-I --I------------- SP-2 .L SP-3 
60 70 80 90 100 
I-I-S-F-Y-L-R-L-F-E-V-L-K-D-N-Q-A-I-S-N-N-I-S-V-I-E-S-H-L-I-T-T-F-F-S-N-S-K-A-K-K-D-A-F-M-S-I-A-K-F- 
- SP-3 , SP-4 & 1‘ SP-5 
110 120 130 136 
R-V-N-N-P-Q-V-Q-R-Q-A-F-N-R-L-I-R-V-V-H-Q-L-L-P-E-S-S-L-R-K-R-K-R-S-R-C 
v SP-6 - SP-7 + SP-8 -_1 
Fig.4. Assignment of peptide fragments obtained by the peptide mapping shown in fig.3 according to their amino acid 
compositions. 
subjected to amino acid analysis for assignment. 
Only eight peaks (SP-1 to SP-8) were assignable 
because other small peaks were non-proteineous or 
not enough to be analyzed. Results of amino acid 
analyses (not shown) suggested that those eight 
peptides explained the complete protein sequence 
except for four residues truncated from the mature 
carboxyl-terminus (fig.4). There was no detectable 
peptide containing the Arg 133-Cys 136 sequence. 
4. DISCUSSION 
The purified rMu-1FN-y consisted of the protein 
sequence xpected from cDNA with the exception 
of the lack of four amino acid residues from the 
mature carboxyl-terminus. It is not clear that the 
processing of carboxyl-terminus like this occurred 
during fermentation or further purification. We 
added some protease inhibitors such as ben- 
zamidine and phenylmethanesulfonyl f uoride to 
buffers for purification to prevent the proteolytic 
processing during the purification procedure. We 
also tried to isolate rMu-IFN-y from the fresh E. 
coli cells harvested at 15 h instead of the usual 24 h 
expecting that a small amount of rMu-IFNy of 
full size might be obtainable, but the carboxyl- 
terminus of the obtained rMu-IFNy was also com- 
pletely truncated. Therefore, the processing 
seemed to occur at the earlier stage of expression 
in cells. The possibility that some amount of full- 
size protein existed but was removed during the 
purification procedure is not deniable. Rinder- 
knecht et al. [13] reported that both 20 kDa and 
25 kDa species of natural human IFN-y derived 
from peripheral blood lymphocytes were 
heterogeneous at their carboxyl-termini, having 
forms which terminated at all residues from Gly 
130 to Met 137 of the mature protein sequence 
predicted from cDNA. It is not clear whether all 
forms are active nor which carboxyl-termini are 
predominant in vivo. The physiological meaning 
of the carboxyl-terminal processing is also still 
unknown. Gribaudo et al. [12] also suggested the 
post-translational proteolytic processing of natural 
murine IFN-y. Rinderknecht and Burton [14] 
showed that about 12 carboxyl-terminal amino 
acid residues were not so important for antiviral 
activity by limited proteolysis of recombinant 
human IFN-y. This is also supported by the fact 
that protein homology between human and murine 
IFNrs is around 40% and a characteristic dif- 
ference is the deletion of nine carboxyl-terminal 
amino acid residues [3]. Moreover, the carboxyl- 
terminal regions of IFNys are supposed to be sub- 
ject to attack by some proteolytic enzymes. 
Availability of rMu-IFN-y will be of great value 
in understanding the biological and physiological 
roles of IFN-)/. Some studies with natural IFN-7 
have been performed, but the possibility that other 
contaminated lymphokines might have affected 
the observations does exist. The rMu-IFN-y will 
clarify those observations and also give sufficient 
opportunities to perform studies in vitro as well as 
in vivo. 
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